This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BREEZE 3 Data For Serada® Presented At 2012 North American Menopause Society Annual Meeting

MENLO PARK, Calif., Oct. 3, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that it is presenting two abstracts from its Phase 3 clinical trial, BREEZE 3, at this week's 23 rd Annual Meeting of the North American Menopause Society (NAMS) in Orlando, FL.  The data showed that Serada ®, Depomed's investigational non-hormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes.

(Logo: )

"Hot flashes are a disruptive problem affecting as many as three out of four menopausal women," said JoAnn V. Pinkerton, M.D., principal investigator of BREEZE 3 and Medical Director of Midlife Health Center, Professor of Obstetrics and Gynecology and Vice Chair of Academic Affairs at the University of Virginia, Charlottesville.  "At this time, hormone therapy is the only approved treatment for hot flashes, yet about 40% of symptomatic women either choose not to go on hormones or are not good candidates.   The BREEZE 3 data findings are important news for women who are looking for more choices to manage their hot flashes and the sleep issues that often accompany them."

BREEZE 3 Statistical Analyses - Non-parametric Analysis vs. ANCOVA Parametric Analysis.  The BREEZE 3 study included 600 menopausal women who were treated with either Serada 1800mg daily (given as one 600mg tablet in the morning and two 600mg tablets at night) or placebo for 24 weeks.  Depomed entered into a Special Protocol Assessment with the FDA with respect to the BREEZE 3 study that specified Depomed would use a non-parametric analysis for the efficacy data from BREEZE 3, and would also perform a supportive parametric ANCOVA statistical analysis.  As previously disclosed, based on the primary non-parametric analysis, efficacy data from the trial were positive and statistically significant for three of the four pre-specified primary endpoints of frequency and severity of hot flashes at four and 12 weeks.  Data for the key secondary endpoints of frequency and severity at 24 weeks did not achieve statistical significance.

The results of the supportive ANCOVA parametric analysis of the BREEZE 3 data were presented at NAMS. In this analysis, Serada significantly reduced the frequency and severity of hot flashes at 4 weeks and 12 weeks compared with placebo.  These reductions were maintained out to 24 weeks.  In addition, an assessment of sleep measures taken at the start of the trial indicated that, on average, women had clinically meaningful improvements in insomnia and sleep disturbance. 

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs